Goldberg, M.* et al. Evaluating the impact of index metastasis resection in patients with multiple brain metastases. Cancers 17, 3281 - 3281 (2025)
Subramanian, N. et al. Superior anti-tumor response after microbeam and minibeam radiation therapy in a lung cancer mouse model. Cancers 17:114 (2025)
Ahmed, M. et al. In vivo microbeam radiation therapy at a conventional small animal irradiator. Cancers 16:581 (2024)
Bauer, L.* et al. Cannabidiol (CBD) protects lung endothelial cells from irradiation-induced oxidative stress and inflammation in vitro and in vivo. Cancers 16:3589 (2024)
Ceballos, F.C.* et al. Inbreeding and gallbladder cancer risk: Homozygosity associations adjusted for indigenous american ancestry, BMI, and genetic risk of gallstone disease. Cancers 16:4195 (2024)
Damirov, F.* et al. Perioperative predictive factors for tumor regression and survival in non-Small cell lung cancer patients undergoing neoadjuvant treatment and lung resection. Cancers 16:2885 (2024)
Muhtadi, R.* et al. Liquid biopsy in whole blood for identification of gene expression patterns (mRNA and miRNA) associated with recurrence of glioblastoma WHO CNS grade 4. Cancers 16:2345 (2024)
Nguyen, N.T.T.* et al. The spectrum of CAR cellular effectors: Modes of action in anti-tumor immunity. Cancers 16:2608 (2024)
Plaza-Díaz, J.* et al. Effect of a novel food rich in miraculin on the oral microbiome of malnourished oncologic patients with dysgeusia. Cancers 16:3414 (2024)
Santiago Franco, M. ; Raulefs, S. ; Schilling, D. ; Combs, S.E. & Schmid, T.E. Impact of radiation on invasion and migration of glioma in vitro and in vivo. Cancers 16:3900 (2024)
Zhao, X.* et al. Identification of genetically predicted DNA methylation markers associated with non–small cell lung cancer risk among 34,964 cases and 448,579 controls. Cancers 130, 913–926 (2024)
Andreu-Sanz, D.* & Kobold, S. Role and potential of different T helper cell subsets in adoptive cell therapy. Cancers 15:18 (2023)
Azimzadeh, O.* et al. Late effects of chronic low dose rate total body irradiation on the heart proteome of ApoE-/- mice resemble premature cardiac ageing. Cancers 15:21 (2023)
Burkart, S.* et al. A novel subgroup of UCHL1-related cancers is associated with genomic instability and sensitivity to DNA-damaging treatment. Cancers 15:16 (2023)
Diehl, C. et al. Dose reduction to motor structures in adjuvant fractionated stereotactic radiotherapy of brain metastases: nTMS-derived DTI-based motor fiber tracking in treatment planning. Cancers 15:282 (2023)
Diehl, C. et al. Low-energy X-ray intraoperative radiation therapy (Lex-IORT) for resected brain metastases: A single-institution experience. Cancers 15:14 (2023)
Diehl, C. et al. Opportunities and alternatives of modern radiation oncology and surgery for the management of resectable brain metastases. Cancers 15:26 (2023)
Foreman, S.C.* et al. Development and Evaluation of MR-Based Radiogenomic Models to Differentiate Atypical Lipomatous Tumors from Lipomas. Cancers 15:14 (2023)
Gong, H.* ; Xue, B.* ; Ru, J. ; Pei, G.* & Li, Y.* Targeted therapy for EWS-FLI1 in ewing sarcoma. Cancers 15:21 (2023)
Hansen, F.J.* et al. Circulating monocytes serve as novel prognostic biomarker in pancreatic ductal adenocarcinoma patients. Cancers 15:13 (2023)
Lin, J.* et al. Cytoreduction of residual tumor burden is decisive for prolonged survival in patients with recurrent brain metastases-retrospective analysis of 219 patients. Cancers 15:13 (2023)
Modena, D.* et al. Identification of a Novel SSTR3 full agonist for the treatment of nonfunctioning pituitary adenomas. Cancers 15:19 (2023)
Spella, M. et al. Non-oncogene addiction of KRAS-mutant cancers to IL-1β via versican and mononuclear IKKβ. Cancers 15:23 (2023)
Starke, S.* et al. Multitask learning with convolutional neural networks and vision transformers for outcome prediction of head and neck cancer patients Cancers 15:21 (2023)
Strand, Z.* et al. Establishment of a 3D model to characterize the radioresponse of patient-derived glioblastoma cells. Cancers 15:14 (2023)
Waltenberger, M.* ; Strick, C.* ; Vogel, M.M.E.* ; Diehl, C. & Combs, S.E. SBRT of spinal metastases using a simultaneous integrated boost concept in oligometastatic cancer patients is safe and effective. Cancers 15:5813 (2023)
Zollner, L.* et al. Gallbladder cancer risk and indigenous South American Mapuche ancestry : Instrumental variable analysis using ancestry-informative markers. Cancers 15:17 (2023)
Blandino, A.* et al. Identification of circulating lncRNAs associated with gallbladder cancer risk by tissue-based preselection, cis-eQTL validation, and analysis of association with genotype-based expression. Cancers 14:634 (2022)
Dumont, M.* et al. Uncovering the contribution of moderate-penetrance susceptibility genes to breast cancer by whole-exome sequencing and targeted enrichment sequencing of candidate genes in women of European ancestry. Cancers 14:3363 (2022)
Erlmeier, F.* et al. MALDI mass spectrometry imaging—prognostic pathways and metabolites for renal cell carcinomas. Cancers 14:1763 (2022)
Gentschev, I.* et al. Tumor colonization and therapy by Escherichia coli nissle 1917 strain in syngeneic tumor-bearing mice is strongly affected by the gut microbiome. Cancers 14:6033 (2022)
Geppert, J. et al. Aging aggravates cachexia in tumor-bearing mice. Cancers 14:90 (2022)
Gulde, S. et al. Combined targeting of pathogenetic mechanisms in pancreatic neuroendocrine tumors elicits synergistic antitumor effects. Cancers 14:5481 (2022)
Hess J. et al. Integration of p16/HPV DNA status with a 24-miRNA-defined molecular 
phenotype improves clinically relevant stratification of head and neck 
cancer patients. Cancers 14:3745 (2022)
Junker, Y.* et al. As easy as 1, 2, 3? How to determine CBCT frequency in adjuvant breast radiotherapy. Cancers 14:4164 (2022)
Kraus, K.M. et al. Treatment planning study for microbeam radiotherapy using clinical patient data. Cancers 14:685 (2022)
Kraus, K.M. et al. Pneumonitis after stereotactic thoracic radioimmunotherapy with checkpoint inhibitors: Exploration of the dose-volume-effect correlation. Cancers 14:2948 (2022)
Küchler, M.* et al. Outcome after radiotherapy for vestibular schwannomas (VS)-differences in tumor control, symptoms and quality of life after radiotherapy with photon versus proton therapy. Cancers 14:1916 (2022)
Lopez-Millan, B.* et al. The multi-kinase inhibitor EC-70124 is a promising candidate for the treatment of FLT3-ITD-positive acute myeloid leukemia. Cancers 14:1593 (2022)
Lyu, C.* et al. Identification of EZH2 as cancer stem cell marker in clear cell renal cell carcinoma and the anti-tumor effect of epigallocatechin-3-gallate (EGCG). Cancers 14:4200 (2022)
Patil, S.* et al. A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT. Cancers 14:3031 (2022)
Sailer, N.* et al. T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety profile and strong anti-tumor reactivity. Cancers 14:1998 (2022)
Schültke, E.* et al. Good Timing Matters: The spatially fractionated high dose rate boost should come first. Cancers 14:5964 (2022)
Tanno, B.* et al. MiRNA-mediated fibrosis in the out-of-target heart following partial-body irradiation. Cancers 14:3463 (2022)
Trassl, L. & Stathopoulos, G.T. KRAS pathway alterations in malignant pleural mesothelioma: An underestimated player. Cancers 14:4303 (2022)
Wagner, A.* et al. Surgical and functional outcome after resection of 64 petroclival meningiomas. Cancers 14:4517 (2022)
Xue, B.* et al. T cells directed against the metastatic driver chondromodulin-1 in ewing sarcoma: Comparative engineering with CRISPR/Cas9 vs. retroviral gene transfer for adoptive transfer. Cancers 14:5485 (2022)
Zhao, X.* et al. Validation of novel molecular imaging targets identified by functional genomic mRNA profiling to detect dysplasia in Barrett's Esophagus. Cancers 14:2462 (2022)
Aftahy, A.K.* et al. Surgical management of jugular foramen schwannomas. Cancers 13:4218 (2021)
Baumeister, P. ; Zhou, J.* ; Canis, M.* & Gires, O. Epithelial-to-mesenchymal transition-derived heterogeneity in head and neck squamous cell carcinomas. Cancers 13:5355 (2021)
Borm, K.J.* et al. Excluding lung tissue from the ptv during internal mammary irradiation. A safe technique for oar-sparing? Cancers 13:1951 (2021)
Borm, K.J.* et al. A comprehensive prospective comparison of acute skin toxicity after hypofractionated and normofractionated radiation therapy in breast cancer. Cancers 13:5826 (2021)
Brunn, D.* et al. Interferon regulatory factor 9 promotes lung cancer progression via regulation of versican. Cancers 13:208 (2021)
Dobiasch, S. et al. Histopathological tumor and normal tissue responses after 3d-planned arc radiotherapy in an orthotopic xenograft mouse model of human pancreatic cancer. Cancers 13:5656 (2021)
Freuer, D.* et al. Body fat distribution and risk of breast, endometrial, and ovarian cancer: A two-sample mendelian randomization study. Cancers 13:5053 (2021)
Gottschlich, A.* ; Endres, S. & Kobold, S. Therapeutic strategies for targeting IL-1 in cancer. Cancers 13:477 (2021)
Gulde, S. et al. Gender-specific efficacy revealed by head-to-head comparison of pasireotide and octreotide in a representative in vivo model of nonfunctioning pituitary tumors. Cancers 13:3097 (2021)
Gutschenritter, T.* et al. The judicious use of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy in the management of large brain metastases. Cancers 13:70 (2021)
Jansen, L.* et al. Estimation of the potentially avoidable excess deaths associated with socioeconomic inequalities in cancer survival in Germany. Cancers 13:357 (2021)
Klymenko, O.* et al. Radiooncological view on therapy outcome after multidisciplinary treatment of sinonasal tumors. Cancers 13:2364 (2021)
Kraus, K.M. et al. Potential morbidity reduction for lung stereotactic body radiation therapy using respiratory gating. Cancers 13:5092 (2021)
Lang, D.M. ; Peeken, J.C. ; Combs, S.E. ; Wilkens, J.J.* & Bartzsch, S. Deep learning based HPV status prediction for oropharyngeal cancer patients. Cancers 13:786 (2021)
Li, W.B. et al. Application of high‐Z gold nanoparticles in targeted cancer radiotherapy—pharmacokinetic modeling, Monte Carlo simulation and radiobiological effect modeling. Cancers 13:5370 (2021)
Madhavan, B.K.* et al. Elevated expression of the rage variant-v in sclc mitigates the effect of chemotherapeutic drugs. Cancers 13:2843 (2021)
Mancini, M.* ; Righetto, M.* & Nößner, E. Checkpoint inhibition in bladder cancer: Clinical expectations, current evidence, and proposal of future strategies based on a tumor-specific immunobiological approach. Cancers 13:6016 (2021)
Merkle, J.* et al. Cdkn2a-mutated pancreatic ductal organoids from induced pluripotent stem cells to model a cancer predisposition syndrome. Cancers 13:5139 (2021)
Mohr, H. et al. Mutation of the cell cycle regulator p27kip1 drives pseudohypoxic pheochromocytoma development. Cancers 13:126 (2021)
Patzelt, L.* et al. Mri‐determined psoas muscle fat infiltration correlates with severity of weight loss during cancer cachexia. Cancers 13:4433 (2021)
Peeken, J.C. et al. Prognostic assessment in high-grade soft-tissue sarcoma patients: A comparison of semantic image analysis and radiomics. Cancers 13:1929 (2021)
Romano, M.* et al. A multi-scale and multi-technique approach for the characterization of the effects of spatially fractionated X-ray radiation therapies in a preclinical model. Cancers 13:4953 (2021)
Schwab, M.* et al. Targeting cancer metabolism breaks radioresistance by impairing the stress response. Cancers 13:3762 (2021)
Sharaf, K.* et al. Human adipose-derived stem/stromal cells promote proliferation and migration in head and neck cancer cells. Cancers 13:2751 (2021)
Spella, M.* & Stathopoulos, G.T. Immune resistance in lung adenocarcinoma. Cancers 13:384 (2021)
Steel, H.* ; Brüningk, S.C.* ; Box, C.* ; Oelfke, U.* & Bartzsch, S. Quantification of differential response of tumour and normal cells to microbeam radiation in the absence of flash effects. Cancers 13:3238 (2021)
Wagner, A.E.* et al. Erratum: Wagner, A.E., et al. SP8 promotes an aggressive phenotype in hepatoblastoma via FGF8 activation. (Cancers 2020, 12, 2294). Cancers 13:362 (2021)
Weusthof, K.* et al. Neurocognitive outcomes in pediatric patients following brain irradiation. Cancers 13:3538 (2021)
Anastasov, N. et al. Mek1 inhibitor combined with irradiation reduces migration of breast cancer cells including mir-221 and zeb1 emt marker expression. Cancers 12:3760 (2020)
Frankó, A. et al. Human prostate cancer is characterized by an increase in urea cycle metabolites. Cancers 12:1814 (2020)
Gambichler, T.* et al. Cancer and immune checkpoint inhibitor treatment in the era of SARS-CoV-2 infection. Cancers 12:3383 (2020)
Kafka, M.* et al. Dual inhibitory action of a novel AKR1C3 inhibitor on both full-length AR and the variant AR-V7 in enzalutamide resistant metastatic castration resistant prostate cancer. Cancers 12:2092 (2020)
Kirstein, A. ; Schmid, T.E. & Combs, S.E. The role of miRNA for the treatment of MGMT unmethylated glioblastoma multiforme. Cancers 12:1099 (2020)
Leger, S.* et al. Comprehensive analysis of tumour sub-volumes for radiomic risk modelling in locally advanced HNSCC. Cancers 12:3047 (2020)
Metz, M.C.* et al. Predicting glioblastoma recurrence from preoperative MR scans using fractional-anisotropy maps with free-water suppression. Cancers 12:728 (2020)
Nguyen, L. et al. The emerging role of miRNAs for the radiation treatment of pancreatic cancer. Cancers 12:3703 (2020)
Shi, R.* et al. A novel gene signature-based model predicts biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. Cancers 12:1 (2020)
Shi, R.* et al. Establishment and validation of an individualized cell cycle process-related gene signature to predict cancer-specific survival in patients with bladder cancer. Cancers 12:1146 (2020)
Wagner, A.E.* et al. SP8 promotes an aggressive phenotype in hepatoblastoma via FGF8 activation, Cancers 12:2294 (2020)
Bechmann, N.* et al. Impact of extrinsic and intrinsic hypoxia on catecholamine biosynthesis in absence or presence of Hif2 alpha in pheochromocytoma cells. Cancers 11:594 (2019)
Dombrowsky, A. et al. Acute skin damage and late radiation-induced fibrosis and inflammation in murine ears after high-dose irradiation. Cancers 11:727 (2019)
Hannen, R.* et al. Comparative transcriptomic analysis of temozolomide resistant primary GBM stem-like cells and recurrent GBM identifies up-regulation of the carbonic anhydrase CA2 gene as resistance factor. Cancers 11:921 (2019)
Kessel, K.A. et al. Patient-reported outcome (PRO) as an addition to long-term results after high-precision stereotactic radiotherapy in patients with secreting and non-secreting pituitary adenomas: A retrospective cohort study up to 17-years follow-up. Cancers 11:1884 (2019)
Koppe, C.* et al. An NF-kappaB- and IKK-independent function of NEMO prevents hepatocarcinogenesis by suppressing compensatory liver regeneration. Cancers 11:999 (2019)
Naumann, P.* et al. Continued weight loss and sarcopenia Ppedict poor outcomes in locally advanced pancreatic cancer treated with chemoradiation. Cancers 11:709 (2019)
Naumann, P.* et al. Cachectic body composition and inflammatory markers portend a poor prognosis in patients with locally advanced pancreatic cancer treated with chemoradiation. Cancers 11:1655 (2019)
Adeberg, S.* et al. Dosimetric comparison of proton radiation therapy, volumetric modulated arc therapy, and three-dimension conformal radiotherapy based on intracranial tumor location. Cancers 10:401 (2018)
Wank, M. et al. Human glioma migration and infiltration properties as a target for personalized radiation medicine. Cancers 10:456 (2018)
Combs, S.E. ; Schmid, T.E. ; Vaupel, P.* & Multhoff, G. Stress response leading to resistance in glioblastoma: The need for innovative radiotherapy (iRT) concepts. Cancers 8:15 (2016)
Multhoff, G. ; Radons, J.R.* & Vaupel, P.W.* Critical role of aberrant angiogenesis in the development of tumor hypoxia and associated radioresistance. Cancers 6, 813-823 (2014)
Slotta-Huspenina, J.* ; Becker, K.F.* ; Feith, M.* ; Walch, A.K. & Langer, R.* Heat Shock Protein 90 (HSP90) and Her2 in adenocarcinomas of the esophagus. Cancers 6, 1382-1393 (2014)